Alnylam Pharmace. buy Stifel Nicolaus
Start price
27.06.24
/
50%
€228.70
Target price
27.06.25
€275.15
Performance (%)
20.16%
End price
28.06.25
€274.80
Summary
This prediction ended on 28.06.25 with a price of €274.80. The BUY prediction by Stifel_Nicolaus finished with a performance of 20.16%. Stifel_Nicolaus has a follow-up prediction for Alnylam Pharmace. where he still thinks Alnylam Pharmace. is a Buy. Stifel_Nicolaus has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Alnylam Pharmace. | 1.240% | 1.240% | 47.084% |
| iShares Core DAX® | 2.659% | 4.844% | 23.110% |
| iShares Nasdaq 100 | 0.916% | -0.554% | 6.985% |
| iShares Nikkei 225® | 2.426% | 1.598% | 15.780% |
| iShares S&P 500 | 1.230% | 1.039% | 4.695% |
Comments by Stifel_Nicolaus for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Stifel Nicolaus from $215.00 to $295.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
In the thread Trading Alnylam Pharmace.
Die von Stifel_Nicolaus gewählte maximale Laufzeit wurde überschritten
Current prediction by Stifel_Nicolaus for Alnylam Pharmace.
Stopped prediction by Stifel_Nicolaus for Alnylam Pharmace.
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€181.40
14.09.23
14.09.23
€225.00
14.09.24
14.09.24
32.41%
15.09.24
15.09.24
